The April 2020 issue of the Society of Toxicology’s official journal, Toxicological Sciences, features leading research in toxicology, including several manuscripts covering emerging technologies, methods, and models.
A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.
A multi-site clinical trial, led by the University of Washington School of Medicine in collaboration with New York University Grossman School of Medicine, aims to definitively determine whether hydroxychloroquine can prevent transmission in people exposed to the virus.
Patients with type 1 diabetes who use Medtronic’s MiniMedTM 670G insulin pump system are able to maintain blood glucose levels in the targeted range over 71% of the time, according to a study that analyzed some 6 million days of real-world data. Results of the industry-supported study were accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental issue of the Journal of the Endocrine Society.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease
Some 4,500 Food and Drug Administration-approved drugs and devices are pulled from shelves annually — decisions greatly influenced by the presence of women on a firm’s board, according to new research from the University of Notre Dame.
Argonne scientists are working around the clock to analyze the virus to find new treatments and cures, predict how it will propagate through the population, and make sure that our supply chains remain intact.
Using a free computer game called Foldit, researchers are enlisting the help of citizen scientists to design drugs that could stop the novel coronavirus from infecting human cells.
UC Davis Health has two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.
There is no data to suggest that continuing allergy and asthma medications will have any effect on increasing your risk of getting the COVID-19 infection, or if you get the infection, lead to a worse outcome.
University of Colorado Cancer Center group shows CPT1A may be necessary for ovarian cancer spread, chemo-resistance. Moves toward clinical trial of CPT1A inhibitor, etomoxir, against chemo-resistant ovarian cancer.
Removing a gene from the cells that produce insulin prevents mice from developing Type 1 diabetes by sparing the cells an attack from their own immune system, a new UW–Madison study shows.
Researchers say they have found a viable new therapeutic strategy for estrogen receptor-positive (ER+) breast cancer, even cancers that are resistant to current standard of care treatments. Their new preclinical study was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
Scientists have found a way in the laboratory to shorten the time it takes to create a key chemical used to synthesize a variety of medications, fertilizers and other important substances. The finding could make a number of industrial manufacturing processes cheaper and more efficient. And all it takes, essentially, is electrifying an aluminum container that includes the right chemicals.
Researchers in the cancer nanomedicine community debate whether use of tiny structures, called nanoparticles, can best deliver drug therapy to tumors passively — allowing the nanoparticles to diffuse into tumors and become held in place, or actively — adding a targeted anti-cancer molecule to bind to specific cancer cell receptors and, in theory, keep the nanoparticle in the tumor longer. Now, new research on human and mouse tumors in mice by investigators at the Johns Hopkins Kimmel Cancer Center suggests the question is even more complicated.
Chemotherapy has been so unsuccessful against DIPG that researchers have questioned whether chemotherapy drugs are even able to reach the cancer. University of Colorado Cancer Center study shows, "... medicine does reach DIPG tissue in good quantities that have the potential to be effective against the tumor," says lead researcher.
SARS-CoV-2, the virus that causes COVID-19, continues to spread, leading to more than 20,000 deaths worldwide in less than four months. Efforts are progressing to develop a COVID-19 vaccine, but it's still likely 12 to 18 months away.
Taking a low-dose aspirin once a day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or probable Alzheimer’s disease, nor does it slow the rate of cognitive decline, according to a large study published in the March 25, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
MD Anderson researchers find that treating T cells with panobinostat and IL-21 re-programs them to a powerful central memory T cell type that persists longer.
Since the discovery of penicillin in 1928 by Sir Alexander Fleming, antibiotics have saved millions of lives from fatal infections world-wide. However, with time bacteria have developed mechanisms to escape the effects of antibiotics - they have become resistant.
In ACS’ Environmental Science & Technology, researchers report that a single pharmaceutical manufacturing facility could be influencing the water quality of one of Europe’s most important rivers.
Physician-scientists at Beth Israel Deaconess Medical Center (BIDMC) are now enrolling patients in two clinical trials testing treatment options for COVID-19, the illness caused by the novel coronavirus. Two trials, led by infectious disease specialist Kathryn Stephenson, MD, MPH, will test the antiviral drug remdesivir for safety and efficacy against the respiratory infection that has sickened more than 300,000 and killed more than 15,000 around the world to date.
Researchers at four University of California Health medical centers have begun recruiting participants for a Phase II clinical trial to investigate the safety and efficacy of treating adult patients with COVID-19 with remdesivir, a drug that has shown promising activity against multiple viruses.
Lawrence Livermore National Laboratory scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics and supercomputing to help discover candidates for new antibodies and pharmaceutical drugs to combat the disease.
Breaking research in AACC’s The Journal of Applied Laboratory Medicine shows that the fentanyl in epidurals can pass on to babies during labor. While the infants in this study did not experience adverse effects from this fentanyl transfer, this information is crucial to ensuring that new mothers don’t get falsely accused of fentanyl abuse, which can have dire social repercussions for mother and child.
The following are various story ideas regarding the COVID-19 illness. To interview Johns Hopkins experts on these topics or others, contact [email protected].
Up until recently, COVID-19 (coronavirus disease 2019) may have been a relatively new phenomena to the general public, but Wichita State University medical chemist Bill Groutas, two virologists from Kansas State University, and a physician/virologist from the University of Iowa have been working on a cure for coronaviruses for more than three years.
Drug therapies that help older adults maintain their skeletal muscle mass and physical function for longer could be a step closer after researchers at the University of Birmingham identify a key mechanism that drives the clearance of damaged mitochondria.
A study led by The University of Texas MD Anderson Cancer Center has found that myelin is surprisingly dynamic, a discovery that has implications for treatment of multiple sclerosis and a type of myelin damage caused by some chemotherapy drugs, often referred to as “chemobrain.”
James Diaz, MD, MHA, MPH & TM, Dr PH, Professor and Head of Environmental Health Sciences at LSU Health New Orleans School of Public Health, has proposed a possible explanation for the severe lung complications being seen in some people diagnosed with COVID-19.
Children with aggressive blood cancers have differences — not just in the DNA code of their blood cells — but also in the heavily twisted protein superstructure that controls access to genes.
April’s edition of SLAS Discovery features the cover article, “Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cell Lines.”
A professor in the Department of Biological Sciences at The University of Alabama in Huntsville (UAH) is part of an effort led by Oak Ridge National Laboratory (ORNL) in Tennessee that applies the power of supercomputers to screen compounds for effectiveness against the pandemic COVID-19 virus.
As COVID-19, the disease caused by the new coronavirus, spreads across the globe, scientists are stepping up to the plate to address the numerous unanswered questions emerging in its wake.
Older patients with prostate, breast, or lung cancer are more likely to be hospitalized after chemotherapy if they take more than five other medicines.
Drugs that are already approved by the U.S. Food and Drug Administration (FDA) could hold promise in fighting the new infection known as coronavirus disease 2019 (COVID-19), according to computer modeling studies performed by UTSW scientists.
“Two independent sources with the same scientific finding make you think it’s true,” says Jean Mulcahy-Levy, MD, investigator at CU Cancer Center and associate professor in the CU School of Medicine Department of Pediatrics.
Advances in treatment have led to the largest yearly declines in deaths due to melanoma ever recorded for this skin cancer, results of a new study suggest.
A paper published today in Clinical Gastroenterology and Hepatology by clinicians at Icahn School of Medicine at Mount Sinai outlines key information gastroenterologists and patients with chronic digestive conditions need to know about COVID-19, or coronavirus.
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers. Open-label Phase II study at MD Anderson reports on four cancer types.
As the global pandemic continues and its impact increasingly disrupts daily life in the U.S., a new ongoing survey launched this week reveals specific concerns about the novel coronavirus among people living with chronic illnesses, who feel these conditions make them more susceptible to the virus (73%) and are beginning to turn to each other (58%) and their doctors (36%) for more information.
LSU researchers are using neutron scattering at ORNL to study crystallization-driven self-assembly, a technique for forming nanoscale solid materials from solutions to understand how the technique could be used to craft controlled-shape nanostructures from polymers known as polypeptoids.
Once-daily treatment of patients with chronic obstructive pulmonary disease (COPD) with an inhaler combining fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) reduced all-cause mortality by 42 percent, according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.
The annual Glaucoma 360 Gala at the Grand Hyatt San Francisco honored leaders in glaucoma research innovation and visionary glaucoma advocates helping to raise awareness.
Physicians describe the standardized procedure of surgical anesthesia for patients with COVID-19 infection requiring emergency surgery to minimize the risk of virus spread and reduce lung injury in a Letter to the Editor published in Surgical Infections, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Proton pump inhibitors – a widely used class of drugs used to treat acid reflux and related symptoms – may lead to an increased risk of fractures in children and adolescents, reports a study in the Journal of Pediatric Gastroenterology and Nutrition (JPGN). Official journal of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, JPGN is published by Wolters Kluwer.
Available evidence supports the use of marked changes in urine oxalate in CKD stages 1-3a and plasma oxalate in CKD stages 3b-5 as surrogate end points for clinical trials in primary hyperoxaluria. Worsening kidney function is considered an acceptable clinical trial end point; however in many patients with primary hyperoxaluria, kidney function is not lost at a rapid rate until very advanced stages of disease. Kidney stones are clinically meaningful, though lack sufficient standards for measurement and monitoring. Their role as a feasible clinical end point should be reconsidered as more data becomes available.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right